buy discount diflucan free shipping

Fox News Flash top headlines for June 17

Fox News Flash top headlines are here. Check out what’s clicking on

Novartis announced on Wednesday that the FDA granted Breakthrough Therapy designation to an experimental therapy that targets advanced castration-resistant prostate cancer. The agency said the decision was based on positive data from a Phase 3 clinical trial evaluating LuPSMA-617. 

Breakthrough Therapy designation is granted to medicines being evaluated for serious conditions where early clinical evidence indicates the potential for substantial improvement over available therapy. 

According to the company, the Phase 3 VISION study demonstrated that the drug significantly improved overall survival and radiographic progression-free survival for men with progressive PSMA-positive mCRPC. 

“Patients with metastatic castration-resistant prostate cancer have a less than 1 in 6 chance of surviving 5 years and need new treatment options,” John Tsai, rosiglitazone prostate cancer head of global drug development and chief medical officer for Novartis, said following promising study results in March. “We would like to thank the patients who volunteered to participate in this study as well as the clinical teams at each of the trial sites. We would not be able to realize our commitment to reimagining medicine without the partnership of patients and their families.” 

Source: Read Full Article